Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features

13 Feb 2020

Abstract excerpt

BACKGROUND: The programmed death receptor ligand 1 (PD-L1) immunohistochemistry (IHC) 22C3 pharmDx assay is a widely used selection method for pembrolizumab treatment in gastric cancer (GC) patients, especially in the U.S. The present study investigated the relationship between PD-L1 expression and the clinical features, molecular markers, and molecular subtypes of GC. METHODS: PD-L1 expression was assessed based...

Topics

Join the communities discussing this publication.

Cancer Immunotherapy and Biomarkers
Ferroptosis and cancer prognosis
Gastric Cancer Management and Outcomes

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 32089413
DOI: 10.1016/j.prp.2020.152881

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular featuresPMID 32089413Read ↗

Impact of programmed death-ligand 1 (PD-L1) positivity on clinical and molecular features of patients with metastatic gastric cancer.Semantic proximity Read ↗

Profiles of PD-1, PD-L1, PD-L2 in Gastric Cancer and Their Relation with Mutation, Immune Infiltration, and Survival.Semantic proximity Read ↗

Clinical Significance of Tumor and Immune Cell PD-L1 Expression in Gastric AdenocarcinomaSemantic proximity Read ↗

Clinicopathological features of Epstein-Barr virus infection, microsatellite instability, tumor mutation burden and PD-L1 status in Chinese patients with gastric cancerSemantic proximity Read ↗

Comprehensive assessment of PD-L1 and PD-L2 dysregulation in gastrointestinal cancers.Semantic proximity Read ↗

Clinicopathological Features of Epstein-Barr Virus Infection, Microsatellite Instability, Tumor Mutation Burden and PD-L1 Status in Chinese Patients with Gastric CancerSemantic proximity Read ↗

Clinicopathological features of tumor mutation burden, Epstein-Barr virus infection, microsatellite instability and PD-L1 status in Chinese patients with gastric cancerSemantic proximity Read ↗

Mutations Defining Patient Cohorts With Elevated PD-L1 Expression in Gastric CancerSemantic proximity Read ↗

PD-L1 overexpression in EBV-positive gastric cancer is caused by unique genomic or epigenomic mechanismsSemantic proximity Read ↗

Polymorphism of the programmed death‐ligand 1 gene is associated with its protein expression and prognosis in gastric cancerSemantic proximity Read ↗

Immunohistochemical‐Based Molecular Typing of ACRG Combined With Immune‐Associated PD ‐ L1 Expression Can Predict the Prognosis of Gastric CancerSemantic proximity Read ↗

Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS-MAPK pathway and TP53 as potential predictors of immunotherapy efficacy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.